FINWIRES · TerminalLIVE
FINWIRES

ブラボー・マイニングの株価は、ブラジルのルアンガ・プロジェクトからの最新分析結果を発表し、1.4%上昇した。

By

-- ブラボー・マイニング(BRVO.V)は火曜日、ブラジルのルアンガ・パラジウム・プラチナ・ロジウム・金・ニッケル鉱床の中央セクターと新たに調査されたクレセントゾーンにおける8本の掘削孔の分析結果を発表した。 主な結果として、白金族金属と金(PGM+Au)が1.9グラム/トン、ニッケルが0.28%の鉱化帯が70メートルにわたって確認された。このうち20メートルはPGM+Auが3.6グラム/トン、ニッケルが0.40%、さらに19メートルはPGM+Auが3.2グラム/トン、8メートルは銅が1.94%、PGM+Auが0.6グラム/トンという高品位鉱化帯であった。 ブラボー社は、これらの結果はルアンガ鉱床の鉱物資源の拡大と質の向上につながる可能性を示していると述べ、これまでに400本の掘削孔を掘削し、うち355本の掘削孔の結果を報告済みであると付け加えた。残りの37本の掘削孔については分析結果待ちである。 「追加掘削では、以前の掘削結果と同等、あるいはそれを上回る厚さと品位の鉱床が継続的に確認されています。今回のプレスリリースに掲載されている掘削断面図からも、品位が引き続き安定しており、孔間、断面間で優れた連続性が見られることが分かります」と、会長兼CEOのルイス・アゼベド氏は述べています。「ルアンガの3つの主要なPGM鉱区外に位置する地域ターゲットであるクレセントゾーンからの良好な結果にも期待を寄せています。クレセントゾーンは、2025年の地球物理探査の完了に伴う再解釈と再データロギングによって特定されました。また、クレセントゾーンの東端で、さらなる調査に値する有望な銅鉱床(DDH26LU307)も確認しました。」 BRVOの株価は、カナダ市場で直近の時点で1.4%上昇しています。

Price: $3.55, Change: $+0.05, Percent Change: +1.43%

Related Articles

Commodities

Avista Q1 Energy Volumes Drop Across Segments Amid Softer Demand

Avista (AVA) reported Q1 earnings Tuesday, with electricity and natural gas volumes declining as milder weather reduced demand, with residential usage down 10% and commercial down 6%.The company reported total residential electricity sales through its operating unit, Avista Utilities, at 1.15 gigawatt-hours, down from 1.27 GWh a year earlier.Electricity sales to the commercial sector were 768 megawatt-hours for the quarter ended March 31, compared with 808 MWh a year earlier.The company reported industrial electricity sales for 455 MWh for the quarter, down from 469 MWh a year earlier, while wholesale sales were 912 MWh, down from 951 MWh a year earlier.The company reported total residential natural gas sales through its operating unit, Avista Utilities, of 8,490.7 billion British thermal units delivered, down from 9,888.1 billion Btu delivered a year earlier.Commercial natural gas sales were 5,116.1 billion Btu delivered for the quarter ended March 31, compared with 5,961.9 billion Btu delivered a year earlier.The company reported wholesale natural gas volumes of 5,446.1 billion Btu delivered in Q1, down from 6,752.8 billion Btu delivered a year earlier.Other natural gas volumes were 5,446.1 billion Btu delivered for the quarter, compared with 5,401.9 billion Btu delivered a year earlier.Avista is also advancing a new enterprise resource planning system targeted for completion in 2028, with estimated capital expenditures of about $130 million to enhance operational efficiency and financial reporting capabilities.Price: $40.81, Change: $+0.25, Percent Change: +0.62%

$AVA
Australia

Primo Brands' Q1 Faces Pressure From Service Disruptions, Cost Headwinds, RBC Says

Primo Brands (PRMB) is expected to face pressure in Q1 from extended service disruptions tied to winter storms and higher input costs linked to the Middle East conflict, RBC Capital Markets said in a note emailed Tuesday.The firm said Q1 is likely to be the weakest quarter of the year and could be further affected by lost or unrecoverable delivery sales from the winter storms.Retail business trends appear supportive, with sales growth of 6% in scanner data, RBC said, adding that the company has taken pricing on about 15% of its retail volume outside its core case pack business.Primo Brands also remains highly sensitive to petroleum-linked costs, including resin, glass, aluminum and diesel fuel, though it has significant hedge coverage in place for 2026 and levers such as pricing and fuel surcharges, the note said.Primo Brands is expected to report Q1 financial results on Thursday.RBC maintained its outperform rating on Primo Brands and kept its price target at $28.Price: $20.37, Change: $+0.27, Percent Change: +1.37%

$PRMB
Australia

BioMarin Enters 'Transition Year' as Enzyme Portfolio Expands After Amicus Deal, Morgan Stanley Says

BioMarin Pharmaceutical (BMRN) is entering a "transition year" in 2026, prioritizing growth acceleration and market share gains as its expanded enzyme portfolio scales following the acquisition of Amicus Therapeutics (FOLD), Morgan Stanley said in a report Tuesday.In its Q1 results, BioMarin raised its fiscal 2026 revenue guidance to $3.825 billion to $3.925 billion, driven by contributions from newly added therapies Galafold and Pombiliti plus Opfolda, but lowered its non-GAAP earnings per share outlook to $4.85 to $5.05 due to integration-related costs and higher interest expenses, associated with the transaction, the report said.BioMarin is focused on scaling its expanded enzyme portfolio and driving commercial execution, with its management expected to outline a detailed roadmap in Q2 covering "long-term revenue potential," peak sales and cost synergies, the investment bank said.Earnings are expected to be weighted toward the second half of 2026, with the Amicus deal seen by the management as "slightly dilutive" this year but "accretive" within 12 months and more meaningful in start of 2027, the report said.The "combined enzyme portfolio" is expected to support durable growth and help offset rising competition for Voxzogo, while pipeline developments and new launches, including Palynziq expansion and BMN-333, could further support long-term growth, according to the report.Morgan Stanley has an overweight rating on BioMarin Pharmaceutical and lowered its price target to $119 from $120.Price: $54.26, Change: $-1.20, Percent Change: -2.16%

$BMRN$FOLD